DBV Technologies expands Scientific Advisory Board with appointment of leading US allergy specialists

Paris, France – 14 June 2010 – DBV Technologies (DBV), a French biotech company specialising in innovative products for food allergy diagnosis and treatment, announced today the appointment of two leading paediatric allergy and allergy specialists Professor N Franklin Adkinson Jr MD and Associate Professor Jonathan M Spergel MD its Scientific Advisory Board.

Professors Adkinson and Spergel are leading authorities in food allergy diagnosis and treatment. These SAB appointments are of strategic importance to DBV Technologies, as the Company is progressing towards its Phase I clinical trial for peanut allergy in the US. Professor Adkinson is a Professor of Medicine at Johns Hopkins Asthma and Allergy Centre. His research has contributed to modern day’s understanding of the mechanisms of allergen immunotherapy.

Professor Spergel is an Associate Professor of Pediatrics at the University Of Pennsylvania School Of Medicine. He is also the Chief of the Allergy department and directs the Centre for Pediatric Eosinophilic Disorders at the Children’s Hospital of Philadelphia. He serves as an international expert on the treatment and diagnosis of food allergies.

Commenting on the appointments, DBV Technologies CEO, Pierre-Henri Benhamou, said, “DBV has continued to strategically build its Scientific Advisory Board over the past year. The experience Professors Spergel and Franklin bring to our Scientific Advisory Board will be invaluable, as we are starting the clinical development of VIASKIN® Peanut in the US and in Europe. This treatment represents a very promising approach of one of the most dangerous allergy and a hopeful solution to one of the major unmet medical need in developed countries.”